Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial

Keyphrases

• 24-month Follow-up 50%
• Bayley Scales of Infant Development-III 50%
• Birth Weight 50%
• Blindness 50%
• BSID-III 50%
• Composite Outcome 50%
• Composite Score 50%
• Early Termination 50%
• Extremely Preterm Infants 50%
• Gestational Age 50%
• Hearing Impairment 50%
• Inositol 50%
• Myo-inositol 100%
• Neonatal Network 50%
• Neurodevelopmental Outcome 100%
• Neurosensory 50%
• NICHD 50%
• Preterm Infants 100%
• Randomized Controlled Trial 100%
• Retinopathy 50%
• Risk of Death 50%
• Severe Cerebral Palsy 50%
• Treatment Group 100%

Medicine and Dentistry

• Amaurosis 33%
• Bayley Scales of Infant Development 33%
• Birth Weight 33%
• Gestational Age 33%
• Group Therapy 66%
• Hearing Impairment 33%
• Inositol 100%
• Randomized Controlled Trial 100%
• Retinopathy 33%
• Spastic Diplegia 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cerebral Palsy 33%
• Hearing Impairment 33%
• Inositol 100%
• Randomized Controlled Trial 100%
• Retinopathy 33%